OnCo

BV-AVD

Checked 2026-09-09

Stage III-IV classical Hodgkin lymphoma

One cycle

every 28 days × 6 · about 24 weeks in total
1781415212228Brentuximab vedotin: 1.2 mg/kg, IntravenousBrentuximab vedotinDoxorubicin: 25 mg/m², IntravenousDoxorubicinVinblastine: 6 mg/m², IntravenousVinblastineDacarbazine: 375 mg/m², IntravenousDacarbazine
28-day cycle × 6 (about 24 weeks)Intravenous

Components

DrugDoseRouteDays
1.2 mg/kgIVD1, 15
Doxorubicin
Cytotoxic chemotherapy (anthracycline)
25 mg/m²IVD1, 15
Vinblastine
Vinca alkaloid (microtubule inhibitor)
6 mg/m²IVD1, 15
Dacarbazine
375 mg/m²IVD1, 15
Cycles
6
28-day cycle
Emetogenicity
High (>90%)
G-CSF
Recommended

Notes

  • Primary G-CSF prophylaxis after excess febrile neutropenia in the trial; peripheral neuropathy in two-thirds.

Used in

Trials

Source

ECHELON-1, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers